Literature DB >> 20878519

Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

David M Thomson1, Allan McVie, Brian J Morris, Judith A Pratt.   

Abstract

BACKGROUND: Cognitive deficits are a core feature of schizophrenia that respond minimally to existing drugs. PCP is commonly used to model schizophrenia-like deficits preclinically although different dosing protocols may affect different domains. Here we characterise the acute, and chronic intermittent effects of PCP in the 5-choice serial reaction time task (5-CSRTT) in rats, and assess the effects of clozapine. In a novel approach, we also assess the effects of increased inhibitory load and conduct clinically relevant signal detection analysis (SDA).
MATERIALS AND METHODS: The effects of acute and repeated PCP (2.58 mg/kg) treatment on attentional processes and inhibitory control were assessed during and following the chronic treatment regime in the presence or absence of chronic clozapine (20 mg/kg/day).
RESULTS: Thirty minutes post-PCP injection, there was an increase in anticipatory responding which disappeared after 24 h. Although, acute PCP did not change accuracy of responding or processing speed, repeated PCP revealed delayed deficits in cognitive processing speed which were partly ameliorated by clozapine. Extended inter-trial intervals increased premature responding, while SDA revealed that clozapine modified persistent PCP-induced deficits in lnBeta (a composite measure of risk taking versus caution).
CONCLUSION: Acute NMDA receptor antagonism impairs inhibitory control, whereas repeated treatment produces delayed deficits in cognitive processing speed. The ability of clozapine partially to restore persistent PCP-induced deficits in processing speed and in lnBeta is consistent with clinical findings. This suggests that the enduring effects of repeated PCP treatment, combined with SDA, offers a useful, translational, approach to evaluate novel cognitive enhancers in the 5-CSRTT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878519     DOI: 10.1007/s00213-010-2020-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  71 in total

1.  Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test.

Authors:  Emily Thaden; Joseph P Rhinewine; Todd Lencz; Hana Kester; Kelly L Cervellione; Inika Henderson; David Roofeh; Katherine E Burdick; Barbara Napolitano; Barbara A Cornblatt; Sanjiv Kumra
Journal:  Schizophr Res       Date:  2005-11-23       Impact factor: 4.939

2.  Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia.

Authors:  W M Perlstein; C S Carter; D C Noll; J D Cohen
Journal:  Am J Psychiatry       Date:  2001-07       Impact factor: 18.112

3.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

4.  Sustained and selective attention as measures of genetic liability to schizophrenia.

Authors:  L A Jones; A G Cardno; R D Sanders; M J Owen; J Williams
Journal:  Schizophr Res       Date:  2001-03-30       Impact factor: 4.939

5.  GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.

Authors:  D A Lewis
Journal:  Brain Res Brain Res Rev       Date:  2000-03

Review 6.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry.

Authors:  T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

7.  Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

Authors:  C A Tamminga; G K Thaker; R Buchanan; B Kirkpatrick; L D Alphs; T N Chase; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1992-07

8.  Reaction time measures of sustained attention differentiate bipolar disorder from schizophrenia.

Authors:  D E Fleck; K W Sax; S M Strakowski
Journal:  Schizophr Res       Date:  2001-12-01       Impact factor: 4.939

9.  The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors.

Authors:  Lucinda J Steward; Matthew D Kennedy; Brian J Morris; Judith A Pratt
Journal:  Neuropharmacology       Date:  2004-09       Impact factor: 5.250

10.  Executive functioning component mechanisms and schizophrenia.

Authors:  John G Kerns; Keith H Nuechterlein; Todd S Braver; Deanna M Barch
Journal:  Biol Psychiatry       Date:  2008-07-01       Impact factor: 13.382

View more
  19 in total

Review 1.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

2.  Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding.

Authors:  S A Barnes; J W Young; S T Bate; J C Neill
Journal:  Behav Brain Res       Date:  2015-11-30       Impact factor: 3.332

3.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 4.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

5.  Convergent observations of MK-801-induced impairment in rat 5C-CPT performance across laboratories: reversal with a D1 but not nicotinic agonist.

Authors:  Andrew J Grottick; David L MacQueen; Samuel A Barnes; Chris Carroll; Erin K Sanabria; Vishal Bobba; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

6.  Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.

Authors:  Sungwon Roh; Susanne S Hoeppner; David Schoenfeld; Catherine A Fullerton; Luke E Stoeckel; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

7.  PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.

Authors:  Anna Castañé; Noemí Santana; Francesc Artigas
Journal:  Psychopharmacology (Berl)       Date:  2015-05-07       Impact factor: 4.530

Review 8.  Stress-induced impairments in prefrontal-mediated behaviors and the role of the N-methyl-D-aspartate receptor.

Authors:  C Graybeal; C Kiselycznyk; A Holmes
Journal:  Neuroscience       Date:  2012-02-28       Impact factor: 3.590

9.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

10.  The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats.

Authors:  Pietro Cottone; Attilio Iemolo; Aditi R Narayan; Jina Kwak; Duncan Momaney; Valentina Sabino
Journal:  Psychopharmacology (Berl)       Date:  2012-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.